Analysts Offer Predictions for Immunovant FY2026 Earnings

Immunovant, Inc. (NASDAQ:IMVT) – Investment analysts at Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for Immunovant in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst L. Chen anticipates that the company will earn ($2.92) per share for the year. The consensus estimate for Immunovant’s current full-year earnings is ($2.75) per share.

A number of other equities analysts also recently commented on the stock. Raymond James restated an “outperform” rating and set a $36.00 price objective on shares of Immunovant in a research note on Thursday, October 10th. Wolfe Research lowered Immunovant from an “outperform” rating to a “peer perform” rating in a research report on Friday, January 3rd. Bank of America cut their price objective on Immunovant from $48.00 to $45.00 and set a “buy” rating for the company in a report on Wednesday, January 15th. HC Wainwright reaffirmed a “buy” rating and set a $51.00 price target on shares of Immunovant in a research report on Friday, November 8th. Finally, Oppenheimer increased their price target on shares of Immunovant from $47.00 to $53.00 and gave the company an “outperform” rating in a research note on Wednesday, October 9th. One equities research analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $47.00.

Immunovant Stock Up 1.4 %

Shares of IMVT stock opened at $23.57 on Thursday. Immunovant has a 12 month low of $22.41 and a 12 month high of $40.12. The company’s fifty day simple moving average is $26.02 and its 200-day simple moving average is $28.42. The firm has a market cap of $3.46 billion, a PE ratio of -10.67 and a beta of 0.66.

Immunovant (NASDAQ:IMVT) last released its earnings results on Thursday, November 7th. The company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.59) by ($0.15). During the same quarter in the previous year, the company posted ($0.45) earnings per share.

Institutional Investors Weigh In On Immunovant

Hedge funds and other institutional investors have recently modified their holdings of the company. KBC Group NV grew its stake in shares of Immunovant by 46.2% in the third quarter. KBC Group NV now owns 1,936 shares of the company’s stock valued at $55,000 after acquiring an additional 612 shares in the last quarter. Assetmark Inc. grew its position in shares of Immunovant by 73.8% during the 3rd quarter. Assetmark Inc. now owns 2,891 shares of the company’s stock worth $82,000 after purchasing an additional 1,228 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Immunovant by 21.4% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,294 shares of the company’s stock worth $148,000 after purchasing an additional 934 shares during the period. Bank Pictet & Cie Europe AG bought a new position in shares of Immunovant during the third quarter worth approximately $261,000. Finally, Scientech Research LLC acquired a new stake in shares of Immunovant in the second quarter valued at approximately $334,000. Institutional investors and hedge funds own 47.08% of the company’s stock.

Insider Activity

In other Immunovant news, CEO Peter Salzmann sold 16,692 shares of the stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $25.45, for a total value of $424,811.40. Following the transaction, the chief executive officer now directly owns 978,097 shares of the company’s stock, valued at $24,892,568.65. This represents a 1.68 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Eva Renee Barnett sold 2,298 shares of the business’s stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $23.83, for a total value of $54,761.34. Following the sale, the chief financial officer now owns 324,766 shares of the company’s stock, valued at approximately $7,739,173.78. This represents a 0.70 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 68,040 shares of company stock valued at $1,697,399 over the last ninety days. 5.90% of the stock is currently owned by company insiders.

Immunovant Company Profile

Immunovant, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia.